[CAS NO. 1207293-36-4] BI-847325
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1207293-36-4]
Distributor
Catalog
SLK-S7843
Brand
Selleck
CAS
1207293-36-4
DESCRIPTION [1207293-36-4]
Overview
| MDL | MFCD28978743 |
|---|---|
| Molecular Weight | 464.56 |
| Molecular Formula | C29H28N4O2 |
| SMILES | O=C(NCC)C#CC1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(CN(C)C)C=C3)/C4=CC=CC=C4 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1526 mL | 10.7629 mL | 21.5257 mL |
| 5 mM | 0.4305 mL | 2.1526 mL | 4.3051 mL |
| 10 mM | 0.2153 mL | 1.0763 mL | 2.1526 mL |
| 50 mM | - | - | - |
Description
BI-847325 is an orally bioavailable, and selective dual inhibitor with of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
Targets
In vitro
BI-847325 shows growth-inhibitory effects on BRAF-mutant and vemurafenib-resistant melanoma cells with IC50 ranging from 0.3 nM to 2 μM, and prevents colony formation in six BRAF-mutant melanoma cell lines. BI-847325 also induces apoptosis by reducing Mcl-1 expression.
In vivo
In mice bearing 1205Lu and 1205LuR xenografts, BI-847325 (75 mg/kg, p.o.) causes significant tumor suppression without significant alteration in the body weights.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.